Use of glucocorticoids in SARS CoV 2 infection: pros and cons

Nicolae Bacinschi, Lucia Ţurcan, Lilia Podgurschi, Ina Gutu, Tatiana Covalschi, Maria Mihalachi-Anghel, Marin Chianu, Anastasia Caracas, E. Vasilache
{"title":"Use of glucocorticoids in SARS CoV 2 infection: pros and cons","authors":"Nicolae Bacinschi, Lucia Ţurcan, Lilia Podgurschi, Ina Gutu, Tatiana Covalschi, Maria Mihalachi-Anghel, Marin Chianu, Anastasia Caracas, E. Vasilache","doi":"10.52556/2587-3873.2021.1(88).01","DOIUrl":null,"url":null,"abstract":"Treatment of SARS CoV-2 infection is a major problem in contemporary medicine caused by the absence of specifi c antiviral drugs. Attempts to use many groups of drugs have had some successes and failures. Th e pathophysiological approach to the rationality of drug use is the basis of the eff ectiveness and safety of treatment. Glucocorticoids are a group of drugs capable of solving health problems in serious and critical situations. Physicians, despite the absence of evidence-based data, continue to use corticosteroids in critical situations based on pharmacological properties and experience. In SARS CoV-2 infection initially, at the beginning of the pandemic, the use of glucocorticoids was not recommended, and later, based on clinical studies, the World Health Organization issued a series of recommendations regarding the rationality of their use through an individualized approach. Th e latter involves determining the timing of initiation, selection of the drug, doses and duration of treatment. Th e key moment in this context is the time of the onset of the cytokine storm (the second week aft er the onset of symptoms) on which the administration of glucocorticoids is directed.","PeriodicalId":269453,"journal":{"name":"Public Health, Economy and Management in Medicine","volume":"47 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public Health, Economy and Management in Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52556/2587-3873.2021.1(88).01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Treatment of SARS CoV-2 infection is a major problem in contemporary medicine caused by the absence of specifi c antiviral drugs. Attempts to use many groups of drugs have had some successes and failures. Th e pathophysiological approach to the rationality of drug use is the basis of the eff ectiveness and safety of treatment. Glucocorticoids are a group of drugs capable of solving health problems in serious and critical situations. Physicians, despite the absence of evidence-based data, continue to use corticosteroids in critical situations based on pharmacological properties and experience. In SARS CoV-2 infection initially, at the beginning of the pandemic, the use of glucocorticoids was not recommended, and later, based on clinical studies, the World Health Organization issued a series of recommendations regarding the rationality of their use through an individualized approach. Th e latter involves determining the timing of initiation, selection of the drug, doses and duration of treatment. Th e key moment in this context is the time of the onset of the cytokine storm (the second week aft er the onset of symptoms) on which the administration of glucocorticoids is directed.
糖皮质激素在SARS冠状病毒感染中的应用:利弊
由于缺乏特异性抗病毒药物,治疗SARS - CoV-2感染是当代医学的一个主要问题。尝试使用多种药物有成功也有失败。病理生理学方法对用药合理性的判断是治疗有效性和安全性的基础。糖皮质激素是一组能够在严重危急情况下解决健康问题的药物。尽管缺乏循证数据,医生仍根据药理学性质和经验在危急情况下继续使用皮质类固醇。在SARS - CoV-2感染中,最初,在大流行开始时,不建议使用糖皮质激素,后来,根据临床研究,世界卫生组织发布了一系列关于通过个体化方法使用糖皮质激素的合理性的建议。后者包括确定起始时间、药物选择、剂量和治疗持续时间。在这种情况下,关键时刻是细胞因子风暴开始的时间(症状开始后的第二周),糖皮质激素的施用是针对的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信